Literature DB >> 33221522

Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019.

Sonali S Bharate1.   

Abstract

Around half of the new molecular entities approved by the US Food and Drug Administration (FDA) are pharmaceutical salts. The pharmaceutical salts have been on a continuous growth trajectory since the approval of the first salt form in 1939. This review aims to provide updates on pharmaceutical salts approved by the FDA between 2015 and 2019. The five-year drug-approval database contains 61 pharmaceutical salts, featuring a diverse range of counterions; however, hydrochlorides are the most abundant. The chemical structures of all pharmaceutical salts in each class are presented here, along with their therapeutic indications and date of approval. The reason behind the selection of a particular counterion and the technical superiority achieved by the salt form over the free active pharmaceutical ingredient base are also discussed.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33221522     DOI: 10.1016/j.drudis.2020.11.016

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  5 in total

1.  BX795-Organic Acid Coevaporates: Evaluation of Solid-State Characteristics, In Vitro Cytocompatibility and In Vitro Activity against HSV-1 and HSV-2.

Authors:  Yogesh Sutar; Tejabhiram Yadavalli; Sagar Kumar Paul; Sudipta Mallick; Raghuram Koganti; Harsh Chauhan; Abhijit A Date; Deepak Shukla
Journal:  Pharmaceutics       Date:  2021-11-12       Impact factor: 6.321

2.  Supramolecular Synthon Promiscuity in Phosphoric Acid-Dihydrogen Phosphate Ionic Cocrystals.

Authors:  Molly M Haskins; Matteo Lusi; Michael J Zaworotko
Journal:  Cryst Growth Des       Date:  2022-04-19       Impact factor: 4.010

3.  Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion fabrication for more robust release profiles.

Authors:  Tu Van Duong; Hanh Thuy Nguyen; Lynne S Taylor
Journal:  Eur J Pharm Biopharm       Date:  2022-04-09       Impact factor: 5.589

Review 4.  Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts.

Authors:  Sonali S Bharate
Journal:  Pharm Res       Date:  2021-07-23       Impact factor: 4.200

5.  Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M B Victor; Aleksandra Drelich; Siva S Panda; Andrea Altieri; Alexander V Kurkin; Chien-Te K Tseng; Christopher D Hillyer; Asim K Debnath
Journal:  Viruses       Date:  2021-12-31       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.